ArticleFrontiers in endocrinology2023

A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer.

Gouling Zhan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.